reviewed april 2026|next review october 2026|88 physicians psi has verified|144 published studies
BPC-157 Arginine Salt
BPC-157 Arginine Salt is a formulation variant of BPC-157 using arginine as the counter-ion instead of acetate, claimed to offer improved gastric stability and oral bioavailability while containing the identical active peptide sequence.
Evidence landscape: 144 published studies
The evidence base is shared with BPC-157. No independent studies on the arginine salt specifically.
- 8 Human
- 107 Animal
- 29 Reviews
The active peptide is identical to standard BPC-157. The arginine counter-ion is a pharmaceutical formulation choice, similar to how ibuprofen comes in different salt forms.
Improved stability in acidic environments (like the stomach), potentially better suited for oral administration. No published comparative data supports this claim.
All BPC-157 research applies to the active peptide. The arginine-specific advantage has no independent validation.
PSI Assessment
BPC-157 arginine salt is the same active peptide as BPC-157, packaged with arginine instead of acetate as the counter-ion. The formulation is marketed as offering improved stability for oral administration. All of BPC-157's tissue repair and gut protection research applies to the active peptide regardless of salt form. The specific claim that the arginine formulation provides superior bioavailability has no published comparative data. For the complete BPC-157 analysis, the BPC-157 flagship page covers the full evidence base.
Same active peptide as BPC-157. Arginine salt may improve gastric stability. No published comparison to acetate salt exists.
The arginine counter-ion may provide buffering capacity and improved thermal stability in acidic environments, making the formulation theoretically better suited for oral administration. Arginine is also an NO-substrate, raising the possibility of additive effects with BPC-157's NO (nitric oxide) system modulation. However, no published study has compared the arginine and acetate salt forms head-to-head for bioavailability, stability, or clinical outcomes.
What the evidence supports
The active peptide (BPC-157) is identical regardless of salt form. All BPC-157 tissue repair, gut protection, and tendon healing evidence applies to the arginine salt. Arginine salt formation is a standard pharmaceutical approach to improving peptide stability in acidic environments.
What is not yet established
Whether the arginine salt form provides clinically superior bioavailability compared to standard BPC-157 acetate. No published head-to-head comparison exists. Whether the arginine moiety adds independent NO-substrate benefits beyond BPC-157 alone.
Research Evidence
The findings below address the formulation rationale. For BPC-157's full research profile, see the BPC-157 compound page.
Evidence by condition
For the BPC-157 evidence matrix, see the BPC-157 compound page.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Gut Protection | ||||
| Tendon Healing |
The active peptide sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) is identical in both the arginine and acetate salt forms. All published BPC-157 research applies regardless of counter-ion.
This is the most important point. The salt form does not change the peptide. The research base is shared.
Arginine salt formation is a standard pharmaceutical approach for improving peptide stability in acidic conditions. The rationale for oral BPC-157 administration is sound because the peptide's GI-protective effects were originally studied via oral routes.
The formulation logic makes pharmaceutical sense. Whether it produces a measurable clinical difference is undemonstrated.
No published head-to-head study compares the bioavailability, stability, or clinical outcomes of BPC-157 arginine salt versus BPC-157 acetate salt.
The absence of comparative data means the arginine formulation advantage remains theoretical.
8 Human|107 Animal|29 Reviews
View all 144 indexed studiesHow BPC-157 Arginine Salt Works
BPC-157 Arginine Salt contains the identical BPC-157 pentadecapeptide sequence with arginine as the counter-ion instead of acetate, intended to improve gastric stability for oral delivery.
Same as BPC-157. Protects and repairs the gut lining, tendons, and other tissues. The arginine salt is just a different way of packaging the same active peptide, similar to how ibuprofen comes in different salt forms.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
The peptide sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) is identical to standard BPC-157. Arginine as counter-ion may provide buffering capacity in acidic environments and improved thermal stability. Arginine is also a nitric oxide substrate, potentially complementing BPC-157's NO system modulation. No published pharmacokinetic comparison exists.
What is BPC-157 Arginine Salt being studied for?
Researchers are studying BPC-157 Arginine Salt across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for BPC-157 Arginine Salt overall. This means a compound can have human studies for one condition but only animal data for another.
Gut Protection
·Human TrialsSame as BPC-157. The active peptide has extensive research on gastric mucosal protection. See BPC-157 compound page for the full analysis.
Limitations: All evidence refers to BPC-157 generically. The arginine salt has no independent clinical data.
Tendon Healing
·Animal StudiesSame as BPC-157. Animal studies show accelerated tendon repair. See BPC-157 compound page.
Limitations: Human trial data for tendon repair with any BPC-157 formulation.
Safety and Regulatory Status
FDA Status: Not FDA-approved. BPC-157 is not approved regardless of salt form.
Availability: Was placed on an FDA list that prevents licensed pharmacies from preparing it. Expected to be restored to the permitted list following the February 2026 HHS announcement.
Class context: Expected to share BPC-157's favorable safety profile from animal studies. Arginine is a naturally occurring amino acid with no inherent toxicity.
Same safety profile as BPC-157. The arginine counter-ion is a naturally occurring amino acid. See BPC-157 compound page for the full safety analysis.
Peptide Structure
Technical molecular data for researchers and clinicians.
Questions and Comparisons
Questions the evidence raises for a BPC-157 Arginine Salt discussion.
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.Comprehensive review of BPC-157 mechanism studies covering the NO system modulation, angiogenesis promotion, and cytoprotective pathways that apply to all salt forms of the peptide, including the arginine salt.Sikiric P et al., 2018 in Curr Pharm Des. View on PubMed
- 2.Documented gastrointestinal protective effects of BPC-157 in animal models, with particular relevance to oral administration where the arginine salt formulation aims to improve gastric stability.Seiwerth S et al., 2014 in Life Sci. View on PubMed
- 3.Review of how BPC-157 activates backup blood-flow pathways to support tissue healing in animal models. The mechanisms described apply to all salt forms of the peptide.Sikiric P et al., 2023 in Curr Med Chem. View on PubMed
- 4.Showed that BPC-157 protects the gastric lining and promotes healing of stomach perforations in rats by regulating nitric oxide signaling, supporting the rationale for an orally stable salt formulation.Sikiric P et al., 2022 in Curr Pharm Des. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.